BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Protalex Doses First Patient in Fourth Cohort of European Phase Ib Study of PRTX-100 in ITP

  The primary study endpoint of the 203 Study is to evaluate the safety of PRTX-100. Secondary endpoints include efficacy, immunogenicity, and pharmacokinetics.

  November 13, 2017

   · 

  4 min read
• GeoVax to Present at the Third International Conference on Vaccines Research and Development

  Dr. Guirakhoo will discuss GeoVax’s vaccine platform which utilizes its recombinant Modified Vaccinia Ankara (MVA) vector to express foreign antigens on virus-like particles (VLPs) in the person being vaccinated.

  November 13, 2017

   · 

  4 min read
• Drug Development

  NousCom’s Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in Preclinical Model

  Nouscom, an oncology company developing next generation cancer vaccines based on its Exovax platform, today announced preclinical data of its neoantigen-based cancer vaccine in combination with Nektar Therapeutics’ NKTR-214, a CD122-biased cytokine agonist which is currently in clinical trials.

  November 13, 2017

   · 

  2 min read
• Business

  Repros Therapeutics Reports Third Quarter 2017 Financial Results

  Net loss for the three month period ended September 30, 2017, was ($1.6) million or ($0.04) per share as compared to a net loss of ($4.2) million or ($0.17) per share for the same period in 2016.

  November 13, 2017

   · 

  7 min read
• Business

  ProPhase Labs Reports Financial Results for the Three Months and Nine Months Ended September 30, 2017

  Net sales from continuing operations were $5.7 million for the nine months ended September 30, 2017, as compared to net sales of $3.4 million for the nine months ended September 30, 2016.

  November 13, 2017

   · 

  10 min read
• Business

  Vote of Confidence in CollPlant: Completion of Agreement for Immediate Investment of USD 1.1 Million From Ami Sagi, One of the Company’s Largest Shareholders

  CollPlant announces that it has signed a private restricted investment agreement with Mr. Ami Sagi, one of the Company’s largest shareholders.

  November 13, 2017

   · 

  2 min read
• Business

  Biohaven Expands Finance Team With Appointment of Senior VP

  Mr. Phillips will focus on further advancing Biohaven’s infrastructure to support the Company’s accounting, external reporting and finance capabilities.

  November 13, 2017

   · 

  2 min read
• 

  Deals

  Sawai Pharma Unloads 20% Stake in Its U.S. Subsidiary for $211M

  The transaction is expected to close by the end of March 2018.

  November 13, 2017

   · 

  3 min read
• Antikor Advances Breakthrough Fragment Drug Conjugate (FDC) Technology Demonstrating Superior Penetration and Tolerability

  Antikor will be presenting new data at the 9th Protein and Antibody Engineering Summit (PEGS) Europe in Lisbon on 14th November, 2017

  November 13, 2017

   · 

  2 min read
• Pharm Country

  Reliefband, Wearable Technology, Provides Relief to Those With Chronic Motion Sickness

  Reliefband Technologies is the leader in providing neuro-stimulation for the drug-free treatment of nausea.

  November 13, 2017

   · 

  2 min read